title: Intravesical resiniferatoxin for patients with neurogenic detrusor overactivity.
abstract: BACKGROUND
  Resiniferatoxin (RTX), a substance isolated from some species of Euphobia, is a specific C-fiber neurotoxin which produces desensitization rather than excitation. At first, we performed intravesical RTX therapy on eight patients with neurogenic detrusor overactivity. After we confirmed the safety and efficacy, a Japanese RTX study group was organized and a new protocol made. The multicenter trial was performed in Japan. However, the efficacy of the treatments was different among the institutions. Therefore, we have compared the results between the first protocol and the new one at our hospital.
  
  
  METHODS
  The first and second protocol involved the RTX solution (30 mL of 500 nM, and 100 mL of 1 micro M, respectively) being instillated in the bladder for 30 min by almost the same procedures. Effects on bladder function were evaluated during treatment and at follow up.
  
  
  RESULTS
  For the first and second protocols, six out of eight patients noted symptomatic improvement while two patients did not notice any change in the degree of incontinence for one month. The mean urodynamic bladder capacity had significantly increased from 138.0 +/- 64.4 mL to 227.3 +/- 112.4 mL and 133.1 +/- 43.3 mL to 247.0 +/- 102.3 mL 1 month after RTX treatment for the first and second protocols, respectively (P < 0.05). No severe side-effects were seen in either group.
  
  
  CONCLUSIONS
  Intravesical RTX improved bladder capacity in patients with neurogenic detrusor overactivity in both protocols. The concentration of RTX did not exhibit any change in the effect and safety in our hospital. Intravesical RTX is a promising treatment for neurogenic detrusor overactivity.
authors.affiliation: Department of Urology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.
authors.forename: Toyohiko
authors.initials: T
authors.lastname: Watanabe
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Katsumi
authors.initials: K
authors.lastname: Sasaki
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Nozaki
authors.forename: Hideo
authors.initials: H
authors.lastname: Ozawa
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kumon
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D002985:Clinical Protocols; D004224:Diterpenes / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009498:Neurotoxins / Q000627:therapeutic use*; D013119:Spinal Cord Injuries / Q000150:complications; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000209:etiology; D014563:Urodynamics / Q000187:drug effects
chemical_list: D004224:Diterpenes; D009498:Neurotoxins; C024353:resiniferatoxin